Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.85 |
| ▸ | NT5E | P21589 | 1/20 | 0.80 |
| ▸ | KRAS | P01116 | 5/20 | 0.79 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.78 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.75 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.71 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.71 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.68 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.67 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HINT1 | P49773 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429843 | 1.00 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL18769114 | 1.00 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL21067722 | 1.00 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL3333959 | 0.97 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL5809658 | 0.97 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL17367368 | 0.97 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL1304258 | 0.97 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL19691775 | 0.97 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL18784960 | 0.97 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL2593095 | 0.97 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389214-A2 | USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN | Thorel, Jean-Noël (FR) | 2024-06-26 | — | — | EP | claimed |
| EP-3466419-B1 | USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN | THOREL JEAN NOEL (FR) | 2024-05-08 | — | — | EP | claimed |
| CN-117050928-B | Sf9 cell strain free of rhabdovirus pollution and efficient screening method thereof | 简达生物医药(南京)有限公司 | 2024-03-05 | — | — | CN | claimed |
| US-20230331809-A1 | FUSION PROTEINS COMPRISING A LIGAND-RECEPTOR PAIR AND A BIOLOGICALLY FUNCTIONAL PROTEIN | ZYMEWORKS BC INC. (CA) | 2023-10-19 | — | — | US | claimed |
| CN-116171167-A | Fusion proteins comprising ligand-receptor pairs and biofunctional proteins | 酵活生物制药有限公司 | 2023-05-26 | — | — | CN | claimed |
| EP-4182357-A1 | FUSION PROTEINS COMPRISING A LIGAND-RECEPTOR PAIR AND A BIOLOGICALLY FUNCTIONAL PROTEIN | Zymeworks BC Inc. (CA) | 2023-05-24 | — | — | EP | claimed |
| WO-2022016270-A9 | FUSION PROTEINS COMPRISING A LIGAND-RECEPTOR PAIR AND A BIOLOGICALLY FUNCTIONAL PROTEIN | ZYMEWORKS BC INC. (CA) | 2023-02-02 | — | — | WO | claimed |
| CN-216629999-U | Filtering device for marine plankton GP4G | 广州奥利生物科技有限公司 | 2022-05-31 | — | — | CN | claimed |
| WO-2022016270-A1 | FUSION PROTEINS COMPRISING A LIGAND-RECEPTOR PAIR AND A BIOLOGICALLY FUNCTIONAL PROTEIN | ZYMEWORKS INC. (CA) | 2022-01-27 | — | — | WO | claimed |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | MODERNATX, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | GENZYME CORP (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4727914-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12594233-B2 | Fat and/or wax activated by means of the water-insoluble fraction of Carica papaya sap | ISP INVESTMENTS LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-7869957-B2 | Methods and systems to identify operational reaction pathways | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100280803-A1 | Compositions and Methods for Modeling Saccharomyces cerevisiae Metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-11-04 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-7751981-B2 | Articles of manufacture and methods for modeling Saccharomyces cerevisiae metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594233-B2 | Fat and/or wax activated by means of the water-insoluble fraction of Carica papaya sap | LIPC, LIPA, PNLIP | TGM2 2897/4885NT5E 2636/4885KRAS 3785/4885 |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PCTP, PLTP | TGM2 3144/4885NT5E 4389/4885KRAS 2659/4885 |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | ELAVL1, IGF2BP2, FUS | TGM2 4209/4885NT5E 3732/4885KRAS 1906/4885 |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | CD2BP2, CD2, CD4 | TGM2 984/4885NT5E 1451/4885KRAS 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.